167158-70-5Relevant articles and documents
Synthesis and application of respiratory syncytial virus inhibitor
-
Paragraph 0119-0124; 0154-0159, (2021/07/24)
The invention provides synthesis and application of a respiratory syncytial virus inhibitor, and the inhibitor comprises a compound with a structure as shown in a formula I or pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label of the compound. Compared with an existing RSV inhibitor, the compound has the advantages of high activity and higher in-vivo exposure.
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Feng, Jun,Zhang, Zhiyuan,Wallace, Michael B.,Stafford, Jeffrey A.,Kaldor, Stephen W.,Kassel, Daniel B.,Navre, Marc,Shi, Lihong,Skene, Robert J.,Asakawa, Tomoko,Takeuchi, Koji,Xu, Rongda,Webb, David R.,Gwaltney II, Stephen L.
, p. 2297 - 2300 (2008/02/05)
Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.